Marijuana, Inc., Completes Acquisition of Exousia AI and Enters Expanding Exosome Market
Marijuana Inc. (OTCPINK: MAJI) has acquired 100% of Exousia AI in a cash and stock transaction, issuing 47 million restricted shares to Ludwig Enterprises with specific lock-up features tied to NASDAQ uplisting. The deal includes assuming liabilities under $75,000 and a $100,000 note.
The acquisition brings worldwide licensed technology for plant-based and human-derived exosomes, including ongoing studies for Glioblastoma treatment and planned studies in dermatology and dental markets. The company will manufacture and sell exosomes for nutraceutical and dermatology markets, targeting the rapidly growing cosmeceuticals sector.
The exosome skincare market is projected to grow from $310 million in 2025 to $633 million in 2033, with a 10% compound annual growth rate. A 30-day treatment currently sells for $400 per vial. The company plans to expand its oncology studies and potentially license its technology to drug manufacturers for enhanced chemotherapy treatments.
Marijuana Inc. (OTCPINK: MAJI) ha acquisito il 100% di Exousia AI in una transazione in contante e in azioni, emettendo 47 milioni di azioni riservate a Ludwig Enterprises con specifiche clausole di lock-up legate all'up listing di NASDAQ. L'affare include l'assunzione di passività sotto i $75,000 e un nota di $100,000.
L'acquisizione porta tecnologia con licenza mondiale per esomi di origine vegetale e umana, incluse ricerche in corso per il trattamento del Glioblastoma e studi pianificati nei mercati della dermatologia e odontoiatria. L'azienda produrrà e venderà esomi per i mercati nutraceutici e dermatologici, mirando al settore in rapida crescita dei cosmeceutici.
Il mercato della skincare a base di esomi è proiettato crescere da $310 milioni nel 2025 a $633 milioni nel 2033, con un tasso di crescita annuale composto del 10%. Un trattamento di 30 giorni attualmente viene venduto a $400 per fiala. L'azienda prevede di espandere i suoi studi oncologici e potenzialmente concedere in licenza la sua tecnologia ai produttori di farmaci per trattamenti di chemioterapia avanzati.
Marijuana Inc. (OTCPINK: MAJI) ha adquirido el 100% de Exousia AI en una transacción de efectivo y acciones, emitiendo 47 millones de acciones restringidas a Ludwig Enterprises con características específicas de clausura vinculadas al uplisting de NASDAQ. El acuerdo incluye la asunción de pasivos por debajo de $75,000 y una nota de $100,000.
La adquisición proporciona tecnología licenciada mundialmente para exosomas derivados de plantas y humanos, incluidos estudios en curso para el tratamiento del Glioblastoma y estudios planeados en los mercados de dermatología y odontología. La empresa fabricará y venderá exosomas para los mercados nutracéuticos y dermatológicos, dirigidos al rápidamente creciente sector de los cosmeceuticos.
Se proyecta que el mercado de cuidado de la piel basado en exosomas crezca de $310 millones en 2025 a $633 millones en 2033, con una tasa de crecimiento anual compuesta del 10%. Un tratamiento de 30 días se vende actualmente por $400 por frasco. La empresa planea expandir sus estudios oncológicos y potencialmente licenciar su tecnología a los fabricantes de medicamentos para tratamientos de quimioterapia mejorados.
Marijuana Inc. (OTCPINK: MAJI)는 100%의 Exousia AI를 현금 및 주식 거래로 인수하였으며, NASDAQ 상장에 따른 특정 잠금 기능이 적용된 4700만 주의 제한 주식을 Ludwig Enterprises에 발행했습니다. 이 거래는 $75,000 미만의 부채를 인수하고 $100,000의 노트를 포함합니다.
이번 인수로 식물 기반 및 인간 유래 엑소좀에 대한 세계적으로 라이센스가 있는 기술이 도입되며, 현재 진행 중인 교모세포종 치료 연구와 피부과 및 치과 시장을 위한 계획된 연구가 포함됩니다. 이 회사는 영양 보충제 및 피부과 시장을 위해 엑소좀을 제조 및 판매할 예정이며, 급속도로 성장하고 있는 화장품 분야를 목표로 하고 있습니다.
엑소좀 스킨케어 시장은 2025년 $310백만에서 2033년 $633백만으로 성장할 것으로 예상되며, 연평균 성장률은 10%입니다. 30일 치료는 현재 바이알당 $400에 판매되고 있습니다. 이 회사는 암 연구를 확장하고 최종적으로 향상된 화학 요법 치료를 위해 제약 회사에 기술을 라이센스할 계획입니다.
Marijuana Inc. (OTCPINK: MAJI) a acquis 100 % d'Exousia AI dans le cadre d'une transaction en espèces et en actions, émettant 47 millions d'actions restreintes à Ludwig Enterprises avec des clauses de blocage spécifiques liées à l'inscription sur le NASDAQ. L'accord comprend l'assumption de passifs ne dépassant pas 75 000 $ et une note de 100 000 $.
Cette acquisition apporte une technologie sous licence mondiale pour des exosomes d'origine végétale et humaine, y compris des études en cours sur le traitement du Glioblastome et des études prévues dans les marchés de la dermatologie et de la dentisterie. L'entreprise fabriquera et vendra des exosomes pour les marchés nutraceutiques et dermatologiques, ciblant le secteur en pleine expansion des cosméceutiques.
Le marché des soins de la peau à base d'exosomes devrait croître de 310 millions de dollars en 2025 à 633 millions de dollars en 2033, avec un taux de croissance annuel composé de 10 %. Un traitement de 30 jours se vend actuellement 400 $ par flacon. L'entreprise prévoit d'élargir ses études oncologiques et envisage potentiellement de concéder sa technologie sous licence à des fabricants de médicaments pour des traitements de chimiothérapie améliorés.
Marijuana Inc. (OTCPINK: MAJI) hat 100% von Exousia AI in einer Bar- und Aktientransaktion übernommen und 47 Millionen beschränkte Aktien an Ludwig Enterprises mit spezifischen Lock-up-Features ausgegeben, die an ein NASDAQ-Listing gebunden sind. Der Vertrag umfasst die Übernahme von Verbindlichkeiten in Höhe von unter $75,000 und eines $100,000-Darlehens.
Die Übernahme bringt weltweit lizenziere Technologie für pflanzenbasierte und menschliche Exosomen mit sich, einschließlich laufender Studien zur Behandlung von Glioblastom und geplanten Studien in den Dermatologie- und Zahnmedizinmärkten. Das Unternehmen wird Exosomen für den nutraceutical und dermatologischen Markt herstellen und verkaufen, mit dem Ziel, den schnell wachsenden Kosmetiksektor zu bedienen.
Der Markt für Exosomen-Hautpflege wird prognostiziert, von 310 Millionen Dollar im Jahr 2025 auf 633 Millionen Dollar im Jahr 2033 zu wachsen, mit einer jährlichen Wachstumsrate von 10%. Eine 30-tägige Behandlung kostet derzeit 400 Dollar pro Ampulle. Das Unternehmen plant, seine onkologischen Studien auszubauen und möglicherweise seine Technologie an Arzneimittelhersteller für verbesserte Chemotherapie-Behandlungen zu lizenzieren.
- Acquisition includes worldwide license for exosome technology
- Access to growing skincare market projected to reach $633M by 2033
- High-margin product with $400 per vial pricing for 30-day treatment
- Ongoing promising studies in Glioblastoma treatment
- Potential for additional revenue through pharmaceutical licensing
- Assumes liabilities under $75,000
- $100,000 note payable to Ludwig
- Significant share dilution with 47 million new shares
- Uplisting requirement for share restriction removal
- Pursing commercial applications in skincare serving a growing market of
The 47,000,000 shares being issued are restricted shares with certain lock-up features. The legend cannot be removed until six months AFTER Exousia Pro has completed its up-listing with NASDAQ or an equivalent exchange. The Company further agreed to assume liabilities under
Exousia AI is a leading
Exousia Pro will manufacture and sell vials of wet exosomes or jars of dried exosomes to the nutraceutical and dermatology markets. The OTC exosome market, known as cosmeceuticals, is rapidly expanding due to consumer demand for antiaging and regenerative skincare solutions. A 30-day treatment for skin and hair sells for
Exousia is in talks to license several other patents using Exosomes, which, once secured, will allow the Company to expand its oncology studies beyond GBM.
When Exousia Pro proves its technology enhances current chemotherapy drugs on the market, it can contact the drug manufacturers and license the tech for use in their drug therapy.
"The exosome market is in its infancy, but poised for explosive growth, as evidence by a surge of promising studies," said CEO of Marijuana Inc., Michael Sheikh. "Mounting research points to the vast therapeutic potential of exosomes, highlighting their capacity to precisely target diseases while minimizing side effects. Investors may not fully appreciate the dominance of monoclonal antibodies, which now lead the pharmaceutical market in revenue. This success stems from their ability to target diseased cells, often delivering therapeutic payloads directly where needed. Every major pharmaceutical company is actively developing monoclonal antibody drugs, driven by the universal desire for treatments that alleviate symptoms without causing new ones."
"Exosomes represent the next generation of targeted therapies, surpassing monoclonal antibodies in several key aspects. They offer significant cost advantages in production, the capacity to deliver larger and more complex payloads, including sensitive molecules like DNA, and a broader range of applications. Importantly, exosomes also mitigate the risk of off-target effects and immune reactions often associated with current monoclonal antibody treatments. This would be a key selling point in the event of licensing discussions. Exosomes embody an elegant evolution in biotechnology, and Exousia Pro is committed to spearheading their commercialization and therapeutic development."
About us
Exousia Pro is a clinical-stage biotechnology company developing new ways to exploit the therapeutic potential of exosomes, initially focused on oncology. The company's patented manufacturing process utilizes plant-based materials to create exosomes used in a number of commercial applications from dermatology to dentistry. The company's proprietary loading technology can infuse a range of molecules from drugs to DNA.
For more information, please visit: www.exousiapro.com
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Ludwig Enterprises Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
CONTACT:
Marijuana, Inc.
www.Exousiapro.com
Twitter: @Exousia_Pro
Investor Relations
ir@exousiapro.com
View original content:https://www.prnewswire.com/news-releases/marijuana-inc-completes-acquisition-of-exousia-ai-and-enters-expanding-exosome-market-302342570.html
SOURCE Marijuana Inc.
FAQ
What are the terms of MAJI's acquisition of Exousia AI?
What is the projected market size for MAJI's exosome skincare products?
What is the pricing strategy for MAJI's exosome treatments?
What clinical studies is MAJI pursuing through the Exousia AI acquisition?
How will the share lock-up period affect MAJI investors?
